Liu J - Search Results

1

Individualized Patient Care Through Model-Informed Precision Dosing: Reflections on Training Future Practitioners.

Jelliffe R, Liu J, Drusano GL, Martinez MN. Jelliffe R, et al. Among authors: liu j. AAPS J. 2022 Nov 15;24(6):117. doi: 10.1208/s12248-022-00769-z. AAPS J. 2022. PMID: 36380020

2

Improper selection of a pre-specified primary dose-response analysis delays regulatory drug approval.

Liu J, Jadhav P, Wang Y, Gobburu J. Liu J, et al. AAPS J. 2013 Apr;15(2):407-14. doi: 10.1208/s12248-012-9438-2. Epub 2013 Jan 10. AAPS J. 2013. PMID: 23307587 Free PMC article.

3

Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.

Bi Y, Liu J, Wang J, Epps RE, Kettl D, Marcus K, Seo S, Zhu H, Wang Y. Bi Y, et al. Among authors: liu j. AAPS J. 2019 Jul 19;21(5):91. doi: 10.1208/s12248-019-0363-5. AAPS J. 2019. PMID: 31325056

4

Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective.

Li RJ, Ma L, Kim H, Kim I, Hanes L, Altepeter T, Lee J, Liu J, Zhu H, Wang Y. Li RJ, et al. Among authors: liu j. AAPS J. 2022 Jul 6;24(4):79. doi: 10.1208/s12248-022-00730-0. AAPS J. 2022. PMID: 35790574 Clinical Trial.

5

Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases.

Li RJ, Ma L, Li F, Li L, Bi Y, Yuan Y, Li Y, Xu Y, Zhang X, Liu J, Bhattaram VA, Wang J, Schuck R, Pacanowski M, Zhu H. Li RJ, et al. Among authors: liu j. J Clin Pharmacol. 2022 Dec;62 Suppl 2:S27-S37. doi: 10.1002/jcph.2143. J Clin Pharmacol. 2022. PMID: 36461744 Review.

6

Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.

Bi Y, Liu J, Li L, Yu J, Bhattaram A, Bewernitz M, Li RJ, Liu C, Earp J, Ma L, Zhuang L, Yang Y, Zhang X, Zhu H, Wang Y. Bi Y, et al. Among authors: liu j, liu c. J Clin Pharmacol. 2019 Sep;59 Suppl 1:S104-S111. doi: 10.1002/jcph.1478. J Clin Pharmacol. 2019. PMID: 31502691 Review.

7

Model-Informed Drug Development in Pediatric Dose Selection.

Bi Y, Liu J, Li F, Yu J, Bhattaram A, Bewernitz M, Li RJ, Ahn J, Earp J, Ma L, Zhuang L, Yang Y, Zhang X, Zhu H, Wang Y. Bi Y, et al. Among authors: liu j. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S60-S69. doi: 10.1002/jcph.1848. J Clin Pharmacol. 2021. PMID: 34185906 Review.

8

Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic.

Xiong Y, Fan J, Kitabi E, Zhang X, Bi Y, Grimstein M, Yang Y, Earp JC, Zheng N, Liu J, Wang Y, Zhu H. Xiong Y, et al. Among authors: liu j. Clin Pharmacol Ther. 2022 Mar;111(3):572-578. doi: 10.1002/cpt.2491. Epub 2021 Dec 4. Clin Pharmacol Ther. 2022. PMID: 34807992 Free PMC article. Review.

9

Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective.

Pan X, Wang L, Liu J, Earp JC, Yang Y, Yu J, Li F, Bi Y, Bhattaram A, Zhu H. Pan X, et al. Among authors: liu j. J Clin Pharmacol. 2023 Nov;63 Suppl 2:S65-S77. doi: 10.1002/jcph.2349. J Clin Pharmacol. 2023. PMID: 37942906 Review.

10

Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.

Yuan Y, Li L, Earp J, Ma L, Bhattaram VA, Sharma V, Tong A, Wang Y, Liu J, Zhu H. Yuan Y, et al. Among authors: liu j. J Clin Pharmacol. 2024 Jul;64(7):799-809. doi: 10.1002/jcph.2418. Epub 2024 Mar 1. J Clin Pharmacol. 2024. PMID: 38426370 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146,180 results

Search Page

Filters